Trial Profile
A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMpower 132
- Sponsors Chugai Pharmaceutical; Roche
- 15 Jan 2023 This trial has been completed in Belgium (End Date: 13 Dec 2022) according to European Clinical Trials Database record.
- 05 Jan 2023 Status changed from active, no longer recruiting to completed.
- 05 Jul 2022 Planned End Date changed from 30 Jun 2022 to 31 Aug 2022.